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The antiretroviral protease inhibitors (APIs) ritonavir, saquinavir, and lopinavir, used to treat HIV infection, inhibit the growth
of Plasmodium falciparum at clinically relevant concentrations. Moreover, it has been reported that these APIs potentiate the
activity of chloroquine (CQ) against this parasite in vitro. The mechanism underlying this effect is not understood, but the de-
gree of chemosensitization varies between the different APIs and, with the exception of ritonavir, appears to be dependent on the
parasite exhibiting a CQ-resistant phenotype. Here we report a study of the role of the P. falciparum chloroquine resistance
transporter (PfCRT) in the interaction between CQ and APIs, using transgenic parasites expressing different PfCRT alleles and
using the Xenopus laevis oocyte system for the heterologous expression of PfCRT. Our data demonstrate that saquinavir behaves
as a CQ resistance reverser and that this explains, at least in part, its ability to enhance the effects of CQ in CQ-resistant P. falcip-
arum parasites.
Certain antiretroviral protease inhibitors (APIs) inhibit thegrowth of malaria parasites at clinically relevant concentra-
tions (2, 21, 23, 25, 32). This observation may have clinically sig-
nificant implications for the treatment of HIV- and malaria para-
site-coinfected patients as well as for the development of a potent
class of antimalarial agents possessing a novel mode of action.
While detailed clinical trials are required to determinewhether the
antiplasmodial activity of the APIs is beneficial in a coinfection
setting, reports that these drugs act synergistically with selected
antimalarial drugs both in vitro and in vivo (13, 14, 31) are prom-
ising, and further studies are clearly warranted.
Initial studies demonstrated that chloroquine (CQ) acts
synergistically with the APIs ritonavir (RTV) and saquinavir
(SQV) against CQ-resistant Plasmodium falciparum parasites
(31). These findings were confirmed and extended by the ob-
servation that CQ also acts synergistically with lopinavir
(LPV), nelfinavir, and atazanavir against CQ-resistant P. fal-
ciparum (14). However, analysis of the activity of CQ-API com-
binations against CQ-sensitive P. falciparum parasites revealed
that (i) the degree of synergy varies among the APIs, with RTV
showing the greatest degree of synergism; (ii) the synergistic
effect of RTV on CQ activity against CQ-resistant P. falciparum
parasites is greater than that measured against CQ-sensitive
parasites; and (iii) although LPV, SQV, nelfinavir, and atazana-
vir behave synergistically with CQ against CQ-resistant P. fal-
ciparum parasites, these combinations are additive when as-
sessed with CQ-sensitive parasites (14).
The mechanism underlying the different effects of CQ-API
combinations against CQ-resistant parasites compared to CQ-
sensitive parasites is not well understood, but one plausible
explanation is that the APIs may act as CQ resistance reversers
in P. falciparum. The primary determinant of CQ resistance in
P. falciparum is mutation of the CQ resistance transporter
(PfCRT) (5, 8, 29, 36). PfCRT is an integral membrane protein
located on the parasite’s digestive vacuole (8), the organelle in
which CQ exerts its antimalarial effects. Using the Xenopus
laevis oocyte expression system, it has been shown that a mu-
tant, resistance-conferring form of PfCRT (PfCRTCQR) trans-
ports CQ, whereas the wild-type form of the protein, found in
CQ-sensitive parasites (PfCRTCQS), does not (20). These data
support the hypothesis that PfCRTCQR confers CQ resistance
by exporting CQ out of the digestive vacuole, away from its
primary site of action. PfCRTCQR-mediated transport of CQ is
inhibited by the resistance reverser verapamil (VP) (20), thus
providing a mechanistic explanation for the ability of this com-
pound to enhance CQ activity in CQ-resistant strains. A num-
ber of other compounds, including peptides (ranging from 4 to
10 residues in length), have also been found to inhibit CQ
transport via PfCRTCQR (20). This finding raises the possibility
that peptidomimetic drugs such as the APIs also interact with
PfCRTCQR and that the CQ-API synergy observed in CQ-resis-
tant parasites results from APIs blocking PfCRTCQR-mediated
CQ efflux from the digestive vacuole.
Here we sought to gain insights into the synergistic interplay
between CQ and APIs in CQ-resistant parasites by examining
the activity of these combinations in previously described
transgenic parasites (29) that share the same genetic back-
ground but express different PfCRT alleles. We also investi-
gated the effects of SQV, RTV, and LPV on CQ accumulation in
these parasites and employed the X. laevis expression system to
test the ability of these APIs to inhibit CQ transport via PfCRT
(20). The results provide new insights into the mechanism un-
derpinning the interplay between CQ and the APIs in their
effects on CQ-resistant parasites.
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MATERIALS AND METHODS
Parasites and culture. The three transgenic parasites used in this study
were generated by Sidhu et al. (29) and were generously provided by
David Fidock (Columbia University, New York, NY). These transgenic
lines were generated fromGCO3, a CQ-sensitive clone derived fromHB3
(36). C4Dd2 and C67G8 were generated by replacing the wild-type pfcrt
GCO3 allele with the CQ resistance-conferring Dd2 and 7G8 alleles, re-
spectively. C2GCO3, the CQ-sensitive transgenic control, contains the
wild-typeGCO3 pfcrt allele. AllP. falciparum parasites weremaintained in
either static (34) or shaking (1) cultures, as described previously. While
transgenic parasites were maintained in the presence of 5 M blasticidin
and 5 nMWR99210, these selection agents were not present during any of
the experimental procedures.
In vitro antimalarial activity and combination assays. Stock solu-
tions of RTV, SQV, and LPV (obtained from the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH) were pre-
pared in 100%dimethyl sulfoxide (DMSO).CQ (diphosphate salt; Sigma)
was prepared in autoclaved distilled water. Dilutions of all drugs were
prepared from stock solutions by use of culture medium when required.
Antimalarial drug combinations were assessed by isobologram analy-
sis as described previously (30). All assays were performed in 96-well
microtiter plates. Each well contained 100 l of cell culture and 100 l of
each drug dilution or control. Plates were then labeled with [3H]hypox-
anthine (0.5 Ci/well; Amersham International, England). After 48 h,
cells were harvested onto filtermats (Harvester 96; Tomtec Incorporated),
and the mats were counted in a model 1450 MicroBeta Plus liquid scin-
tillation counter. All such experiments were performed on at least three
separate occasions.
Isobolograms were constructed using data from all experiments.
Briefly, the concentration of each drug that alone or in combination
resulted in 50% inhibition of parasite growth (i.e., the IC50) was plot-
ted as the fractional inhibitory concentration (FIC) (3). Using the
SAAM II program (SAAM Institute, Seattle, WA), a standard hyper-
bolic function (4), i.e., Yi  1  {Xi/[Xi  e
I  (1  Xi)]} (where Yi
is the IC50 for drug A combined with drug B, Xi is the IC50 for drug B
combined with drug A, and I is the interaction value), was fitted to the
data. Positive values of I indicate synergism, negative values indicate
antagonism, and an I value of 0 indicates that the effects of the two
compounds are simply additive. The significance of the difference of I
from zero (P values of 0.01 indicate an additive interaction) was
assessed using Student’s t test.
Measurements of chloroquine accumulation in P. falciparum-in-
fected erythrocytes.The accumulation of [3H]CQ (20 nM [20Ci/mmol];
American Radiolabeled Chemicals) in mature trophozoite-infected
erythrocytes (36 h postinvasion) was measured using a protocol de-
scribed in full elsewhere (19).
Measurements of chloroquine transport in X. laevis oocytes ex-
pressing PfCRT. Expression of mutant and wild-type forms of PfCRT
(from strains Dd2 and D10, respectively) at the plasma membrane of X.
laevis oocytes was achieved as described previously (20). Briefly, oocytes
were injected with cRNA encoding PfCRT (30 ng per oocyte), and the
uptake of [3H]CQ (0.3M[15Ci/mmol];Moravek) wasmeasured at 4 to
6 days postinjection as described previously (20). Uptake measurements
were made over 1 to 2 h at 25°C in medium that contained 96 mMNaCl,
2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 10 mM morpholineethanesul-
fonic acid (MES), 10 mM Tris base (pH 6.0), and 15 M unlabeled CQ.
Statistical comparisons were made with Student’s t test for unpaired sam-
ples or with analysis of variance (ANOVA) in conjunction with Tukey’s
multiple comparison test.
RESULTS
Combinations of chloroquine with saquinavir are more effec-
tive against CQ-resistant lines than against CQ-sensitive para-
sites. Isobolograms describing the interactions of CQ with SQV
against CQ-sensitive (C2GCO3) and CQ-resistant (C4Dd2 and
C67G8) lines demonstrate that the antiplasmodial activity of these
drugs used in combination is dependent on the PfCRT allele ex-
pressed. When combinations of SQV and CQ were assessed
against parasites expressing the Dd2 PfCRTCQR allele, an additive
interaction was observed (Fig. 1) (I  0.1; P  0.1). However,
the same combination behaved antagonistically in control para-
sites expressing the wild-type GCO3 allele (Fig. 1) (I4.7; P
0.0005). In contrast, combinations of CQ with RTV or LPV be-
haved antagonistically against all transgenic parasites (Fig. 1).
Saquinavir partially restores chloroquine accumulation in
CQ-resistant P. falciparum, whereas ritonavir and lopinavir do
not.CQ resistance-reversing agents such as verapamil can be used
in vitro to resensitize resistant parasites to CQ (albeit partially).
This verapamil-induced chemosensitization is associated with an
increased accumulation of CQ in resistant parasites, but no such
change in CQ accumulation occurs in CQ-sensitive parasites
treated with verapamil (20). To investigate the possibility that
SQV potentiates the effects of CQ via the samemechanism as that
for verapamil and other resistance reversers, CQ accumulation
was measured in the C2GCO3, C4Dd2, and C67G8 lines in the pres-
ence or absence of verapamil, SQV, RTV, and LPV. Under control
conditions, the CQ accumulation ratios for the CQ-resistant
C4Dd2 and C67G8 lines were 14.1 2.0 and 13.7 2.7 times lower
(mean standard error of the mean [SEM]; n 4), respectively,
than that measured for the CQ-sensitive C2GCO3 line (data not
shown). Verapamil (1 M) had no effect on CQ accumulation in
the C2GCO3 parasites but caused a 2.5-  0.2-fold increase in the
CQ accumulation ratio in the C4Dd2 line and a less dramatic,
1.8- 0.1-fold increase in the C67G8 line (P 0.05; paired t tests)
(Fig. 2a to c), consistent with previous reports (20). SQV (0.5 or 1
M) also increased CQ accumulation in the CQ-resistant lines,
with similar fold increases (1.5- to 1.7-fold) in both the C4Dd2 and
C67G8 parasites (P  0.05; paired t tests). In contrast, RTV (1 or
2.25M) and LPV (0.5, 1, or 4.3M) had either little or no effect
on the CQ accumulation ratio or caused it to decrease by similar
levels across all three strains. Indeed, all of the APIs tested, includ-
ing SQV, significantly decreased the CQ accumulation ratio in
C2GCO3 parasites (P 0.01; paired t tests), with the one exception
being the 1 M RTV treatment, which gave a ratio that was not
statistically different from the C2GCO3 control ratio. Thus, SQV
decreased the CQ accumulation ratio in the CQ-sensitive line by
1.3- to 1.4-fold yet caused a 1.5- to 1.7-fold increase in the resistant
lines, consistent with the observed ability of SQV to antagonize
CQ activity in the C2GCO3 line and to enhance its activity in C4Dd2
and C67G8 parasites (Fig. 1).
Inhibition of chloroquine transport via PfCRTCQR by
saquinavir and ritonavir. The finding that SQV increased CQ
accumulation in CQ-resistant parasites led us to investigate
whether this effect is mediated by blockade of CQ transport via
PfCRTCQR, as shown previously for verapamil (20). The expres-
sion of PfCRT in X. laevis oocytes enables direct measurements of
CQ transport via PfCRTCQR, and thus an assessment of inhibition
of CQ transport by potential resistance reversers. The direction of
CQ transport in the PfCRT expression system is from the mildly
acidic extracellular medium (pH 6.0) into the oocyte cytosol (pH
7.2), which corresponds to the efflux of CQ from the acidic diges-
tive vacuole (pH 5 to 5.5) (12) into the parasite cytosol (pH 7.3)
(27). A key advantage of the oocyte system is that it allows PfCRT
to be studied directly and in isolation, without confounding ef-
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fects such as the binding of drugs to heme or interactions of the
compound with other targets or transporters.
In an initial experiment in which the APIs were tested at an
extracellular concentration of 500 M, SQV abolished CQ
transport via PfCRTCQR, RTV reduced PfCRTCQR-mediated
transport by 66%, and LPV had no effect (Fig. 3a). An anal-
ysis of the concentration-dependent inhibition of CQ trans-
port by SQV yielded an IC50 of 13 1 M (mean SEM; n
4) (Fig. 3b). This value is significantly lower than that measured
for verapamil (30  3 M [20]; P  0.01 by unpaired t test),
which makes SQV the most potent inhibitor of PfCRTCQR
identified to date.
DISCUSSION
Understanding the pharmacokinetic and pharmacodynamic in-
teractions between APIs and antimalarial drugs is important if
such combinations are to form the basis of treatment regimens. In
this study, we found an antagonistic interaction between CQ and
SQV against the CQ-sensitive C2GCO3 parasite line, whereas an
additive interaction occurred against the CQ-resistant parasite
lines C4Dd2 and C67G8 (Fig. 1). These three transgenic cell lines
differ only in the version of pfcrt that they harbor—the wild type
or the 7G8 or Dd2 variant. The data therefore indicate that the
variants of PfCRT encoded by the Dd2 and 7G8 alleles influence
the parasite’s response to CQ-SQV combinations. In contrast,
the activities of the CQ-LPV andCQ-RTV combinations were not
dependent on the pfcrt allele carried by the parasite, as an antago-
nistic interactionwas observedwith these combinations against all
transgenic parasites.
These findings differ somewhat from those of previous stud-
ies, which reported synergistic and additive (rather than addi-
tive and antagonistic) interactions when SQV-CQ combina-
tions were assessed against CQ-resistant and CQ-sensitive
strains of P. falciparum, respectively (13, 14, 31). This apparent
anomaly may be due to the genetic background shared by the
FIG 1 Isobolograms describing the interactions of SQV with CQ, RTV with CQ, and LPV with CQ against erythrocytes infected with C2GCO3, C4Dd2, or
C67G8 parasites. Titration experiments were performed at least three times in triplicate. Data derived from all experiments are shown. Interaction values
were derived from all data, and the significance of the difference of I from zero (P values of 0.01 indicate an additive interaction) was assessed using
Student’s t test. Interaction values for chloroquine and saquinavir combinations were calculated to be 4.7 (P  0.0005), 0.1 (P  0.1), and 0.1 (P 
0.1) for C2GCO3, C4Dd2, and C67G8 parasites, respectively. Interaction values for chloroquine and ritonavir combinations were calculated to be 2.2
(P  0.01), 2.5 (P  0.01), and 1.9 (P  0.01) for C2GCO3, C4Dd2, and C67G8 parasites, respectively. Interaction values for chloroquine and
lopinavir combinations were calculated to be 2.1 (P  0.001), 5.0 (P  0.001), and 2.3 (P  0.05) for C2GCO3, C4Dd2, and C67G8 parasites,
respectively.
Inhibition of PfCRT by Saquinavir
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transgenic parasite lines. All of the previous data reporting
synergy between CQ and SQV or CQ and RTV were generated
using Dd2 parasites. Likewise, the additive effect of the CQ-
SQV combination in CQ-sensitive parasites has been shown
only with 3D7 parasites. Although GCO3 parasites are the
progeny of an HB3 Dd2 cross, they nevertheless contain key
differences from their CQ-resistant Dd2 parent. For example,
the GCO3 line possesses a single pfmdr1 (P. falciparum multi-
drug resistance transporter 1) allele, whereas the Dd2 line con-
tains four (7, 36). Moreover, the Dd2 PfMDR1 protein differs
from the GCO3 version at positions 86 (Y instead of N) and
1042 (N instead of D) (28, 33, 36). Since PfMDR1 is thought to
play a role in mediating drug resistance in the parasite (26, 28),
it is conceivable that the single copy number and sequence
variation harbored by the GCO3 lines affected the ability of
SQV and RTV to potentiate CQ activity. For instance, perhaps
overexpression of the Dd2 variant of PfMDR1 serves to provide
an additional route for the influx of APIs into the digestive
vacuole—leading to increased levels of APIs in the compart-
ment where they can compete with CQ for efflux via PfCRT—
and this route is diminished or abolished in GCO3 parasites. It
should also be noted that the version of PfMDR1 expressed by
the 3D7 line differs from that carried by the GCO3 lines, at
position 1042 (N instead of D) (9). Thus, the activity of the
CQ-API combinations had not previously been tested against
the form of PfMDR1 carried by the GCO3 lines. In this regard,
it is worth noting that Yuan and colleagues reported that LPV
and, to a lesser extent, SQV displayed a 5-fold or more differ-
ence in antiplasmodial activity between P. falciparum strains
from different backgrounds and/or geographical regions (38).
Further analysis of the differential sensitivity patterns for LPV
revealed that the magnitude of its IC50 was significantly asso-
ciated with mutations in PfCRT and PfMDR1 and that P. fal-
ciparum lines which differed only in the version of PfMDR1
that they carried showed significantly different susceptibilities
to LPV. These findings support the idea that the response of
GCO3 lines to APIs is likely to differ from those of Dd2 and
3D7 and that this could be due, at least in part, to the different
forms and copy numbers of pfmdr1 harbored by these para-
sites. Other differences between GCO3 and Dd2 (and between
GCO3 and 3D7) may also cause CQ-API combinations to exert
differential activity upon these strains. This is the first study
that has attempted to control for these variables by testing
CQ-API combinations against the C2GCO3, C4Dd2, and C67G8
lines, which differ only in the version of PfCRT that they ex-
press. Given that PfMDR1 is also likely to play a role in the
parasite’s response to CQ-API combinations, it would be inter-
esting to evaluate these combinations in lines of parasites that
differ only in the version and/or copy number of pfmdr1.
Consistent with its ability to act in concert with CQ in the
C4Dd2 and C67G8 lines and to antagonize its activity in the C2GCO3
line, SQV was found to increase the accumulation of CQ in the
former and cause a reduction in CQ accumulation in the latter
(Fig. 2). Indeed, SQV displayed resistance reversal activity in the
C67G8 line that was comparable to that of verapamil. The presence
of RTV or LPV caused modest to significant reductions in the
accumulation of CQ in the three GCO3 lines, which also corre-
lated well with their antagonistic interactions with CQ in these
parasites. The finding that SQV, RTV, and LPV all caused a de-
crease in CQ accumulation in C2GCO3 parasites within the 1-h
FIG 2 Effects of SQV, RTV, and LPV on [3H]CQ accumulation by erythrocytes
infected with mature trophozoite-stage parasites. Panels a, b, and c show data for
theparasite linesC2GCO3,C4Dd2, andC67G8, respectively.Theaccumulationassays
were performed over 1 h at 37°C and with an initial [3H]CQ concentration of 20
nM. CQ accumulation is expressed in terms of the fold difference in the [3H]CQ
accumulation ratio (i.e., the concentration of radiolabeled CQwithin the infected
cells relative to the concentration in the extracellularmedium).Thedata represent
the means plus SEM for four independent experiments.
Martin et al.
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incubation time of the assay is intriguing. Perhaps the APIs reduce
the amount of heme (the target of CQ) in the digestive vacuole by
inhibiting hemoglobin digestion, which in turn would lead to a
decrease in the accumulation of heme-CQ complexes in the vac-
uole. Alternatively, the APIs may affect CQ accumulation by in-
fluencing the pH gradient and/or membrane potential across the
vacuole membrane.
Experiments using the Xenopus oocyte system revealed that
SQV and, to a lesser extent, RTV interact directly with Dd2
PfCRTCQR to inhibit CQ transport. SQV displayed significant ac-
tivity against Dd2 PfCRTCQR, with an IC50 that was about half that
measured for verapamil (Fig. 3) (20). The fact that SQV acts as a
CQ resistance reverser in C67G8 parasites (Fig. 2) suggests that it
also has the ability to inhibit the transport of CQ via 7G8
PfCRTCQR. It is likely that in order to reverse CQ resistance, SQV
gains access to and accumulates within the digestive vacuole via
simple diffusion and/or carrier-mediated transport. Like vera-
pamil and the quinoline drugs, SQV can behave as a weak base
(pKa values of 1.1 and 7.1 [Ka is the acid dissociation constant]
[10, 16]) (Fig. 4) and is therefore expected to accumulate in the
acidic environment of the vacuole via weak-base trapping. In con-
trast, the pKa values for LPV andRTV are below 3 (10, 18) (Fig. 4),
and hence these compounds are expected to be largely nonionized
within the digestive vacuole and therefore not subject to weak-
base trappingwithin this compartment. LPV andRTV are also less
lipophilic than SQV and are less likely to transverse membranes
via simple diffusion in their uncharged states (10). Furthermore,
SQV more closely mimics the peptidomimetic design of classic
protease inhibitors (whereas RTV and LPV were designed to be
more stable and less peptidomimetic in nature); this may explain
in part its superior ability in blocking PfCRTCQR (37), since this
protein has previously been shown to be inhibited by a number of
peptides (20).
Differences in the physicochemical properties of SQV and
verapamil may also explain why SQV is the more potent inhib-
itor of Dd2 PfCRTCQR in the oocyte system (Fig. 3) (20) but less
effective than verapamil at increasing the accumulation of CQ
in C4Dd2 parasites (Fig. 2). For instance, verapamil (pKa of 9
[11]) is expected to reach a higher concentration than SQV
within the vacuole via weak-base trapping. In any case, the fact
that SQV caused a decrease in CQ accumulation in the C2GCO3
line makes it difficult to compare its resistance-reversing activ-
ities in the C4Dd2 and C67G8 parasites with those of verapamil;
the observed level of CQ accumulation in CQ-resistant para-
sites treated with SQV is likely to be the net result of SQV’s
ability to increase accumulation via inhibition of PfCRTCQR
while simultaneously causing a decrease in accumulation via an
as yet unknown mechanism.
Taken together, these findings provide new insights into
why CQ-SQV combinations are more effective against CQ-
resistant P. falciparum parasites than against CQ-sensitive
strains. The data demonstrate that in addition to its intrinsic
antiplasmodial activity, SQV can act as a CQ resistance re-
verser, and that it exerts this effect (at least in part) by inhibit-
ing the transport of CQ via PfCRTCQR. Hence, SQV can be
considered a potential dual-function antimalarial that could be
used in combination with CQ (or other quinoline antimalari-
als) against P. falciparum. The clinical consequences of this CQ
resistance-reversing activity have yet to be explored. CQ and
SQV are both largely discarded drugs—the emergence of resis-
tant parasites has rendered CQ largely ineffective (except when
double-dose regimens are employed [35]), and SQV has been
superseded by next-generation APIs. Nevertheless, new CQ-
like drugs that are effective against CQ-resistant parasites are
being developed (6, 15, 17, 24) and are undergoing clinical
trials (22), and these could be paired with a next-generation
SQV that possesses intrinsic antimalarial activity as well as the
ability to inhibit mutant PfCRT. This would place an additional
FIG 3 Effects of APIs on CQ uptake via PfCRTCQR. (a) [3H]CQ uptake into oocytes expressing Dd2 PfCRTCQR (black bars) or D10 PfCRTCQS (white bars)
in the presence of 500 M unlabeled SQV, RTV, or LPV. SQV and RTV (P  0.001; ANOVA), but not LPV (P  0.05; ANOVA), caused significant
reductions in CQ uptake via PfCRTCQR. Rates of CQ uptake (pmol h1 per oocyte; n  4) under control conditions were 0.87  0.05 and 6.4  0.5
(mean SEM) for PfCRTCQS- and PfCRTCQR-expressing oocytes, respectively. (b) Concentration-dependent inhibition by SQV of the uptake of [3H]CQ
into oocytes expressing Dd2 PfCRTCQR (solid circles) or D10 PfCRTCQS (open circles). The IC50 derived from these data (13  1 M) was obtained by
least-squares fit of the equation Y Ymin {(Ymax Ymin)/(1 ([inhibitor]/IC50)
C)}, where Y is PfCRTCQR-mediated CQ transport, Ymin and Ymax are
the minimum and maximum values of Y, and C is a constant. PfCRTCQR-mediated CQ transport was calculated by subtracting the uptake measured in
oocytes expressing D10 PfCRTCQS from that in oocytes expressing Dd2 PfCRTCQR. In both panels, uptake is shown as the mean  SEM for four
independent experiments, within which measurements were made for 10 oocytes per treatment. Note that noninjected oocytes and oocytes expressing
PfCRTCQS take up [3H]CQ to similar (low) levels via simple diffusion of the neutral species; this represents the “background” level of CQ accumulation
in oocytes (refer to reference 20 for full data and a detailed discussion).
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selection pressure on the parasite and its quinoline resistance
mechanism and may thereby extend the longevity of both the
quinoline antimalarial and its API partner drug.
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